Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: Value of diagnostic tools prior to desensitization

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 7, 2015, Pages 784-794

  Alvarez Cuesta, E ^a   Madrigal Burgaleta, R ^a   Angel Pereira, D ^a   Urena Tavera A ^a   Zamora Verduga, M ^a   Lopez Gonzalez, P ^a   Berges Gimeno, M P ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

chemotherapy agents; desensitization; drug provocation test; oxaliplatin; specific IgE

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL PRODUCT; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; FOLINIC ACID; GEMCITABINE; INFLIXIMAB; IRINOTECAN; OXALIPLATIN; PACLITAXEL; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; ALLERGEN; BIOLOGICAL FACTOR; IMMUNOGLOBULIN E; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; DESENSITIZATION; DIAGNOSTIC VALUE; DRUG HYPERSENSITIVITY; DRUG PROVOCATION TEST; FEMALE; GOLD STANDARD; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHENOTYPE; PREDICTIVE VALUE; PRICK TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROVOCATION TEST; RISK ASSESSMENT; SKIN TEST; VERY ELDERLY; ADOLESCENT; BLOOD; CHILD; IMMUNOLOGY; MIDDLE AGED; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLERGENS; ANTINEOPLASTIC AGENTS; BIOLOGICAL FACTORS; CHILD; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PHENOTYPE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SKIN TESTS; YOUNG ADULT;

EID: 84931565938     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12620     Document Type: Article

References (36)

1. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, et al., Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58: 854-863.
2. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al., International consensus on drug allergy. Allergy 2014; 69: 420-437.
3. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010; 105: 259-273.
4. Picard M, Castells MC,. Re-visiting hypersensitivity reactions to taxanes: a comprehensive review. Clin Rev Allergy Immunol; in press. DOI 10.1007/s12016-014-8416-0.
5. Vultaggio A, Castells MC,. Hypersensitivity reactions to biologic agents. Immunol Allergy Clin North Am 2014; 34: 615-632.
6. Hsu Blatman KS, Castells MC,. Desensitizations for chemotherapy and monoclonal antibodies: indications and outcomes. Curr Allergy Asthma Rep 2014; 14: 453.
7. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC,. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009; 124: 1259-1266.
8. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al., Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122: 574-580.
9. Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, et al., Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 2009; 123: 1262-1267.
10. Gastaminza G, de la Borbolla JM, Goikoetxea MJ, Escudero R, Anton J, Espinos J, et al., A new rapid desensitization protocol for chemotherapy agents. J Investig Allergol Clin Immunol 2011; 21: 108-112.
11. Wong JT, Ling M, Patil S, Banerji A, Long A,. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract 2014; 2: 40-45.
12. Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, et al., General considerations on rapid desensitization for drug hypersensitivity-a consensus statement. Allergy 2010; 65: 1357-1366.
13. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Alvarez-Cuesta E, et al., Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 2013; 68: 853-861.
14. Ureña-Tavera A, Zamora-Verduga M, Madrigal-Burgaleta R, Angel-Pereira D, Berges-Gimeno MP, Alvarez-Cuesta E,. Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations. J Allergy Clin Immunol. 2015; 135 1066-1067.
15. Alvarez-Cuesta E, Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D,. Rapid desensitization to chemotherapy and monoclonal antibodies is effective and safe. Reply. Allergy 2013; 68: 1483-1484.
16. Angel-Pereira D, Berges-Gimeno MP, Madrigal-Burgaleta R, Urena-Tavera MA, Zamora-Verduga M, Alvarez-Cuesta E,. Successful rapid desensitization to methylprednisolone sodium hemisuccinate: a case report. J Allergy Clin Immunol Pract 2014; 2: 346-348.
17. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Guillen-Ponce C, Sanz ML, Alvarez-Cuesta E,. Desensitizing oxaliplatin-induced fever: a case report. J Investig Allergol Clin Immunol 2013; 23: 435-436.
18. Brown SG,. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004; 114: 371-376.
19. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P,. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57: 45-51.
20. Simons FE, Ardusso LR, Bilo MB, Dimov V, Ebisawa M, El-Gamal YM, et al., 2012 update: world allergy organization guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol 2012; 12: 389-399.
21. Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al., Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs)-classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA. Allergy 2011; 66: 818-829.
22. Blanca M, Romano A, Torres MJ, Fernandez J, Mayorga C, Rodriguez J, et al., Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 2009; 64: 183-193.
23. Bonadonna P, Lombardo C, Bortolami O, Bircher A, Scherer K, Barbaud A, et al., Hypersensitivity to proton pump inhibitors: diagnostic accuracy of skin tests compared to oral provocation test. J Allergy Clin Immunol 2012; 130: 547-549.
24. Salas M, Gomez F, Fernandez TD, Dona I, Aranda A, Ariza A, et al., Diagnosis of immediate hypersensitivity reactions to radiocontrast media. Allergy 2013; 68: 1203-1206.
25. Blanca-Lopez N, J Torres M, Dona I, Campo P, Rondon C, Seoane Reula ME, et al., Value of the clinical history in the diagnosis of urticaria/angioedema induced by NSAIDs with cross-intolerance. Clin Exp Allergy 2013; 43: 85-91.
26. Romano A, Blanca M, Torres MJ, Bircher A, Aberer W, Brockow K, et al., Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy 2004; 59: 1153-1160.
27. Demoly P, Romano A, Botelho C, Bousquet-Rouanet L, Gaeta F, Silva R, et al., Determining the negative predictive value of provocation tests with beta-lactams. Allergy 2010; 65: 327-332.
28. Berges-Gimeno MP, Simon RA, Stevenson DD,. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003; 90: 338-341.
29. Hope AP, Woessner KA, Simon RA, Stevenson DD,. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2009; 123: 406-410.
30. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J,. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000; 18: 102-105.
31. Pagani M,. The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am 2010; 94: 835-852.
32. Roy-Byrne PP, Craske MG, Stein MB,. Panic disorder. Lancet 2006; 368: 1023-1032.
33. Schwartz JR, Bandera C, Bradley A, Brard L, Legare R, Granai CO, et al., Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? the experience from women and infants' hospital. Gynecol Oncol 2007; 105: 81-83.
34. Pagani M, Bonadonna P,. Skin test protocol for the prevention of hypersensitivity reactions to oxaliplatin. Anticancer Res 2014; 34: 537-540.
35. Patil SU, Long AA, Ling M, Wilson MT, Hesterberg P, Wong JT, et al., A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. J Allergy Clin Immunol 2012; 129: 443-447.
36. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al., Skin test concentrations for systemically administered drugs-an ENDA/EAACI drug allergy interest group position paper. Allergy 2013; 68: 702-712.